Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Cogent Biosciences Inc

Healthcare US COGT

38.0USD
1.69(4.65%)

Last update at 2026-06-24T17:56:00Z

Day Range

36.4738.60
LowHigh

52 Week Range

4.3043.73
LowHigh

Fundamentals

  • Previous Close 36.31
  • Market Cap5961.60M
  • Volume3425312
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-330.79901M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -121.62700M
  • Diluted EPS TTM-2.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -328.93700M -255.85900M -192.41000M -140.24100M -72.27300M
Minority interest - - - - -
Net income -328.93700M -255.85900M -192.41000M -132.64300M -71.80600M
Selling general administrative 63.58M 43.28M 34.38M 26.21M 19.64M
Selling and marketing expenses - - 34.34M - -
Gross profit -4.61900M -4.40100M -3.58800M - -
Reconciled depreciation 4.58M 4.35M 3.73M 5.88M 0.15M
Ebit -333.36300M -275.93900M -208.13000M -153.71700M -75.55100M
Ebitda -328.74400M -271.58800M -204.54200M -147.83900M -75.40400M
Depreciation and amortization 4.62M 4.35M 3.59M 5.88M 0.15M
Non operating income net other - - - 7.60M 3.28M
Operating income -333.36300M -275.93900M -208.13000M -147.83900M -75.55100M
Other operating expenses 333.36M 275.94M 208.13M 147.84M 75.55M
Interest expense 3.06M 0.00000M 0.00000M 3.99M 3.13M
Tax provision - - - - -
Interest income 14.69M 18.09M 11.32M 3.99M 0.47M
Net interest income 11.63M 18.09M 11.32M 3.99M 0.47M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -7.59800M -0.46700M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 328.74M 275.94M 208.13M 147.84M 75.55M
Cost of revenue 4.62M 4.40M 3.59M - -
Total other income expense net 4.43M 20.08M 15.72M 7.60M 3.28M
Discontinued operations - - - - -
Net income from continuing ops -328.93700M -255.85900M -177.66300M -140.24100M -72.27300M
Net income applicable to common shares - - - -140.24100M -72.27300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 937.61M 327.90M 313.44M 300.81M 232.09M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.59M 9.39M 5.06M 5.69M 2.95M
Total liab 301.24M 71.61M 55.63M 45.08M 17.91M
Total stockholder equity 636.37M 256.29M 257.80M 255.74M 214.18M
Deferred long term liab - - - - -
Other current liab 52.90M 42.13M 0.44M 17.88M 3.29M
Common stock 0.16M 0.11M 0.09M 0.07M 0.04M
Capital stock 89.55M 110.71M 60.12M 65.90M 85.44M
Retained earnings -1188.42000M -859.48300M -603.62400M -411.21400M -270.97300M
Other liab - - - - -
Good will - - - - -
Other assets - - - 4.75M 4.98M
Cash 312.01M 98.17M 53.23M 139.89M 219.68M
Cash and equivalents - - - - -
Total current liabilities 63.95M 55.71M 38.17M 26.85M 17.08M
Current deferred revenue - - 25.69M 1.70M 7.97M
Net debt -58.86000M -80.69800M -34.37600M -120.23700M -216.52900M
Short term debt 1.55M 1.56M 1.39M 1.42M 2.32M
Short long term debt - - - - -
Short long term debt total 253.15M 17.47M 18.85M 19.65M 3.15M
Other stockholder equity 1734.88M 1004.61M 801.06M 601.15M 399.71M
Property plant equipment - - - 7.78M 1.71M
Total current assets 910.36M 296.47M 270.77M 264.97M 222.63M
Long term investments - 0.00000M 7.46M - -
Net tangible assets - - - 189.91M 128.78M
Short term investments 588.75M 188.91M 212.48M 119.39M -
Net receivables - - - - -
Long term debt 222.90M - - - -
Inventory - - - - -
Accounts payable 9.50M 12.01M 10.65M 5.84M 3.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.35M 0.45M 0.25M -0.10400M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.07M 0.04M
Preferred stock total equity - - - 65.83M 85.40M
Retained earnings total equity - - - -411.21400M -270.97300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.72M 4.86M 4.86M 4.75M 4.98M
Deferred long term asset charges - - - - -
Non current assets total 27.25M 31.43M 42.67M 35.84M 9.46M
Capital lease obligations 15.90M 17.47M 18.85M 19.65M 3.15M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -397.97200M 38.28M -79.90200M -117.85500M -1.71900M
Change to liabilities - - - 11.95M 6.18M
Total cashflows from investing activities -399.52600M 38.28M -97.82400M -124.71800M -1.71900M
Net borrowings 217.76M 0.00000M 0.00000M - -
Total cash from financing activities 878.23M 214.45M 163.54M 163.56M 37.98M
Change to operating activities - - - -1.60800M -0.73100M
Net income -328.93700M -255.85900M -192.41000M -140.24100M -72.27300M
Change in cash 214.26M 44.94M -87.91200M -79.79800M -22.50600M
Begin period cash flow 98.17M 53.23M 141.14M 220.94M 243.44M
End period cash flow 312.43M 98.17M 53.23M 141.14M 220.94M
Total cash from operating activities -264.44400M -207.79100M -153.62400M -118.63800M -58.76300M
Issuance of capital stock 159.32M 213.34M 161.82M 161.94M 38.01M
Depreciation 4.58M 4.35M 3.59M 5.88M 0.15M
Other cashflows from investing activities - 38.28M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - 0.00000M
Sale purchase of stock - - - 1.61M 0.06M
Other cashflows from financing activities -48.89600M 1.11M 1.72M 1.61M -0.03000M
Change to netincome - - - 18.37M 11.69M
Capital expenditures 1.55M 0.57M 2.80M 6.86M 1.72M
Change receivables - - - - -
Cash flows other operating - - - -7.91400M -4.50500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -79.79800M -22.50600M
Change in working capital 8.01M 11.60M 11.44M 0.75M 2.02M
Stock based compensation 46.08M 39.74M 30.62M 18.37M 11.69M
Other non cash items 5.82M -7.61900M -6.86500M -3.39400M -0.34300M
Free cash flow -265.99800M -208.36400M -156.42000M -125.50100M -60.48200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
COGT
Cogent Biosciences Inc		 1.69 4.65% 38.00 - - 861.15 10.98 929.31 -3.8852
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Cogent Biosciences Inc

275 Wyman Street, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Andrew R. Robbins M.B.A. Pres, CEO & Director 1976
Dr. John Edward Robinson Ph.D. Chief Scientific Officer NA
Dr. Jessica Sachs M.D. Chief Medical Officer 1975
Mr. John L. Green C.A., CPA CFO & Principal Accounting Officer 1980
Mr. Brad Barnett Chief Technology Officer NA
Mr. Evan D. Kearns J.D. Chief Legal Officer & Corp. Sec. 1980
Ms. Erin Schellhammer Chief People Officer NA
Ms. Sara Saltzman Sr. VP of Regulatory Affairs NA
Mr. Dana R. Martin Pharm.D. Sr. VP of Medical Affairs & Chief Patient Officer NA
Brad Fell VP & Head of Medicinal Chemistry NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.